A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Cognitive Disorders

In brief

The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of SUVN-G3031 in healthy male subjects following single or multiple ascending doses.

Key facts

Study ID

NCT02342041

Run by

Suven Life Sciences Limited

People needed

64

Starts

2014-09-01

Expected to finish

2015-08-01

Last updated by the study team

2016-10-14

Who can join

Age: 18 and older, up to 45. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy male aged 18 to 45 years with a BMI between 18 and 30 kg/m2, (inclusive).

You may not qualify if…

• Standard exclusion criterion for Phase 1 clinical trial in healthy subjects.
• History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate
• History or presence of GI, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs as judged by Investigator.

Where it is running

• Quintiles — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.